Cargando…

B.P.F.C.® Bio-Plasma® with Pure Growth Factors (BioPlasma®) Used for the Treatment of a Persistent Great Periapical Lesion of an Endodontically Treated Tooth: A New Therapeutic Option

The aim of this case report was to evaluate the efficacy of a new platelet-rich plasma preparation and its regenerative capacity of bone periapical tissue for the treatment of a very compromised endodontic treated tooth, with a periapical lesion of 1.5 cm in diameter, using a pure platelet concentra...

Descripción completa

Detalles Bibliográficos
Autores principales: Viganò, Raffaello, Disconzi, Mirko, Bertini, Edoardo, Viganò, Luca, Casu, Cinzia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7341431/
https://www.ncbi.nlm.nih.gov/pubmed/32685218
http://dx.doi.org/10.1155/2020/4876437
_version_ 1783555238360252416
author Viganò, Raffaello
Disconzi, Mirko
Bertini, Edoardo
Viganò, Luca
Casu, Cinzia
author_facet Viganò, Raffaello
Disconzi, Mirko
Bertini, Edoardo
Viganò, Luca
Casu, Cinzia
author_sort Viganò, Raffaello
collection PubMed
description The aim of this case report was to evaluate the efficacy of a new platelet-rich plasma preparation and its regenerative capacity of bone periapical tissue for the treatment of a very compromised endodontic treated tooth, with a periapical lesion of 1.5 cm in diameter, using a pure platelet concentrate. This is made without the use of anticoagulant or any type of activator, e.g., bovine thrombin, calcium chloride. For this reason, it has been called “Pure”; it is the B.P.F.C.® Bio-Plasma® with Pure Growth Factors (BioPlasma®) designed and developed by Dr. Raffaello Viganò. The patient has read and signed a written consent form. The study protocol was approved by the Ethics Committee for Human Studies, University of Varese. X-ray at 2 and 6 months and 4 years after endodontic surgery demonstrated the success of the treatment.
format Online
Article
Text
id pubmed-7341431
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-73414312020-07-17 B.P.F.C.® Bio-Plasma® with Pure Growth Factors (BioPlasma®) Used for the Treatment of a Persistent Great Periapical Lesion of an Endodontically Treated Tooth: A New Therapeutic Option Viganò, Raffaello Disconzi, Mirko Bertini, Edoardo Viganò, Luca Casu, Cinzia Case Rep Dent Case Report The aim of this case report was to evaluate the efficacy of a new platelet-rich plasma preparation and its regenerative capacity of bone periapical tissue for the treatment of a very compromised endodontic treated tooth, with a periapical lesion of 1.5 cm in diameter, using a pure platelet concentrate. This is made without the use of anticoagulant or any type of activator, e.g., bovine thrombin, calcium chloride. For this reason, it has been called “Pure”; it is the B.P.F.C.® Bio-Plasma® with Pure Growth Factors (BioPlasma®) designed and developed by Dr. Raffaello Viganò. The patient has read and signed a written consent form. The study protocol was approved by the Ethics Committee for Human Studies, University of Varese. X-ray at 2 and 6 months and 4 years after endodontic surgery demonstrated the success of the treatment. Hindawi 2020-06-29 /pmc/articles/PMC7341431/ /pubmed/32685218 http://dx.doi.org/10.1155/2020/4876437 Text en Copyright © 2020 Raffaello Viganò et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Viganò, Raffaello
Disconzi, Mirko
Bertini, Edoardo
Viganò, Luca
Casu, Cinzia
B.P.F.C.® Bio-Plasma® with Pure Growth Factors (BioPlasma®) Used for the Treatment of a Persistent Great Periapical Lesion of an Endodontically Treated Tooth: A New Therapeutic Option
title B.P.F.C.® Bio-Plasma® with Pure Growth Factors (BioPlasma®) Used for the Treatment of a Persistent Great Periapical Lesion of an Endodontically Treated Tooth: A New Therapeutic Option
title_full B.P.F.C.® Bio-Plasma® with Pure Growth Factors (BioPlasma®) Used for the Treatment of a Persistent Great Periapical Lesion of an Endodontically Treated Tooth: A New Therapeutic Option
title_fullStr B.P.F.C.® Bio-Plasma® with Pure Growth Factors (BioPlasma®) Used for the Treatment of a Persistent Great Periapical Lesion of an Endodontically Treated Tooth: A New Therapeutic Option
title_full_unstemmed B.P.F.C.® Bio-Plasma® with Pure Growth Factors (BioPlasma®) Used for the Treatment of a Persistent Great Periapical Lesion of an Endodontically Treated Tooth: A New Therapeutic Option
title_short B.P.F.C.® Bio-Plasma® with Pure Growth Factors (BioPlasma®) Used for the Treatment of a Persistent Great Periapical Lesion of an Endodontically Treated Tooth: A New Therapeutic Option
title_sort b.p.f.c.® bio-plasma® with pure growth factors (bioplasma®) used for the treatment of a persistent great periapical lesion of an endodontically treated tooth: a new therapeutic option
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7341431/
https://www.ncbi.nlm.nih.gov/pubmed/32685218
http://dx.doi.org/10.1155/2020/4876437
work_keys_str_mv AT viganoraffaello bpfcbioplasmawithpuregrowthfactorsbioplasmausedforthetreatmentofapersistentgreatperiapicallesionofanendodonticallytreatedtoothanewtherapeuticoption
AT disconzimirko bpfcbioplasmawithpuregrowthfactorsbioplasmausedforthetreatmentofapersistentgreatperiapicallesionofanendodonticallytreatedtoothanewtherapeuticoption
AT bertiniedoardo bpfcbioplasmawithpuregrowthfactorsbioplasmausedforthetreatmentofapersistentgreatperiapicallesionofanendodonticallytreatedtoothanewtherapeuticoption
AT viganoluca bpfcbioplasmawithpuregrowthfactorsbioplasmausedforthetreatmentofapersistentgreatperiapicallesionofanendodonticallytreatedtoothanewtherapeuticoption
AT casucinzia bpfcbioplasmawithpuregrowthfactorsbioplasmausedforthetreatmentofapersistentgreatperiapicallesionofanendodonticallytreatedtoothanewtherapeuticoption